A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-Chloro-3- methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners

Journal of Medicinal Chemistry

Volumn 48, Issue 20, 2005, Pages 6326-6339

  Mylari, Banavara L ^a   Armento, Sandra J ^a   Beebe, David A ^a   Conn, Edward L ^a   Coutcher, James B ^a   Dina, Michael S ^a   O'Gorman, Melissa T ^a   Linhares, Michael C ^a   Martin, William H ^a   Oates, Peter J ^a   Tess, David A ^a   Withbroe, Gregory J ^a   Zembrowski, William J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,4 DICHLOROPHENYLSULFONYL) 2H PYRIDAZIN 3 ONE; 6 (5 CHLORO 3 METHYLBENZOFURAN 2 SULFONYL) 2H PYRIDAZIN 3 ONE; ALDEHYDE REDUCTASE INHIBITOR; MINALRESTAT; OXIDOREDUCTASE INHIBITOR; PHENYL GROUP; POLYOL; PONALRESTAT; RANIRESTAT; SORBINIL; TOLRESTAT; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALDEHYDE REDUCTASE; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DIABETES MELLITUS, EXPERIMENTAL; FRUCTOSE; HUMANS; HYPOGLYCEMIC AGENTS; LENS, CRYSTALLINE; MALE; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SCIATIC NERVE; SORBITOL; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 26444477394     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050462t     Document Type: Article

References (62)

1. (a) Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. Diabetes Care 2004, 27, 1047-1053.
2. (b) Zimmet, P. Z.; Alberti, K. G. M. M.; Shaw, J. Global and Societal Implications of the Diabetes Epidemic. Nature 2001, 414, 782-787.
3. American Diabetes association. Economic Costs of Diabetes in the US in 2002. Diabetes Care 2003, 26, 917-932.
4. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977-986.
5. U. K. Prospective Diabetes Study Group. Intensive Blood-glucose Control with Sulfonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). Lancet 1998, 352, 837-853.
6. (a) Hers, H. G. Le Méchnaisme de la Transformation de Glucose en Fructose par les Véscicules Seminales. Biochim. Biophys. Acta 1956, 22, 202-203.
7. (b) Hers, H. G. L'Aldose Reductase. Biochim. Biophys. Acta 1960, 37, 120-126.
8. (a) Van Heyningen, R. Formation of Polyols by Lens of the Rat with "Sugar" Cataract. Nature 184, 194-195, 1959.
9. (b) Gabbay, K. H.; Merola, L. O.; Field, R. A. Sorbitol Pathway: Presence in Nerve and Cord with Substrate Accumulation in Diabetes. Science 1966, 151, 209-210.
10. (c) Gabbay, K. H. The Sorbitol Pathway and Complications of Diabetes. N. Engl. J. Med. 1973, 194, 1085-1087.
11. (d) Oates, P. J. The Polyol Pathway and Diabetic Complications. In The Neurobiology of Diabetic Neuropathy; Tomlinson, D. R., Ed.; Academic Press: London, 2002; Vol 50, pp 325-392.
12. (a) Kinoshita, J. H. A Thirty Year Journey in the Polyol Pathway. Exp. Eye. Res. 1990, 50, 567-573.
13. (b) Kinoshita, J. H.; Nishimura, C. The Involvement of Aldose Reductase in Diabetic Complications. Diabetes Metab. Rev. 1988, 4, 323-337.
14. (a). Tilton, R. G.; Chang, K.; Nyengaard, J. R.; Van den. Enden, M.; Ido, Y.; Williamson, J. R. Inhibition of Sorbitol Dehydrogenase. Effects on Vascular and Neural Dysfunction in Streptozotocin-induced Diabetic rats. Diabetes 1995, 44, 234-242.
15. (b) Williamson, J. R.; Chang, K.; Frangos, M.; Hasan, K. S.; Ido, Y.; Kawamura, T.; Nyengaard, J. R.; Van den Enden, M.; Kilo, C.; Tilton, R. G. Hypergylcemic Pseudohypoxia and Diabetic Complications. Diabetes 1993, 42, 801-813.
16. (a) Geisen, K.; Utz, R.; Grotsch, H.; Lang, J.; Nimmesgern, H. Sorbitol-accumulating Pyrimidines: Arzneim. Forsch./Drug Res. 1994, 44, 1032-1043.
17. (b) Mylari, B. L.; Oates, P. J.; Beebe, D. A.; Brackett, N. S.; Coutcher, J. B.; Michael S. Dina, M. S.; Zembrowski, W. J. Sorbitol Dehydrogenase Inhibitors (SDIs): A New Potent, Enantiomeric SDI, 4-[2-(1R-Hydroxy-ethyl)- pyrimidin-4-yl]-piperazine-1-sulfonic Acid Dimethylamide. J. Med. Chem. 2001, 44, 2695-2700.
18. Cameron, N. E.; Cotter, M. A.; Basso, M.; Hohman, T. C. Comparison of the Effects of Inhibitors of Aldose Reductase and Sorbitol Dehydrogenase on Neurovascular Function, Nerve Conduction and Tissue Polyol Pathway Metabolites in Streptozotocin-Diabetic Rats. Diabetalogia 1997, 40, 271-281.
19. Ao, S.; Shingu, Y.; Kikuchi, C.; Takano, Y.; Nomura, K.; Fujiwara, T.; Ohkubo, Y.; Notsu, Y.; Yamaguchi, I. Characterization of a Novel Aldose Reductase Inhibitor, FR74366, and Its Effects on Diabetic Cataract and Neuropathy in the Rat. Metabolism 1991, 40, 77-87.
20. Eggler, J. F.; Larson, E. R.; Lipinski, C. A.; Mylari, B L.; Urban, F. J. In Advances in Medicinal Chemistry; Maryanoff, E., Maryanoff, C. A., Eds.; Jai Press Inc.: London, 1993; Vol. 2, pp 197-246.
21. (a) Beyer-Mears, A.; Cruz, E.; Edelist, T.; Varagiannis, E. Diminished Proteinuria in Diabetes Mellitus and Its Prevention by Sorbinil, an Aldose Reductase Inhibitor. Pharmacology 1986, 32, 52-60.
22. (b) Goldfarb, S.; Simmons, D. A.; Kern, E. F. O. Amelioration of Glomerular Hyperfiltration in Acute Experimental Diabetes Mellitus by Dietary Myo-inositol Supplementation and Aldose Reductase Inhibition. Trans. Assoc. Am. Physicians 1986, 99, 67-72.
23. (c) Oates, P. J.; Ellery, C. A. Aldose Reductase Inhibitor Zopolrestat Prevents Elevated Urinary Albumin Excretion in Diabetic Rats. Diabetes 1992, 41 (supplement 1), A121.
24. (d) Oates, P. J.; Ellery, C. A. Aldose Reductase Inhibitor Zopolrestat Reduces Hyperfiltration and Albuminuria in Diabetic Rats. Diabetes 1992, 41 (supplement 1), A148.
25. (e) Pedersen, M. M.; Christiansen, J. S.; Mogensen, C. E. Reduction of Glomerular Hypertension in Normoalbuminuric IDDM Patients by 6 Months of Aldose Reductase Inhibition. Diabetes 1991, 40, 527-531.
26. (a) Ramasamy, R.; Truebloode, N.; Schaefer, S. Metabolic Effects of Aldose Reductase Inhibition During Low-Flow Ischemia and Reperfusion. Am. J. Physiol. 1998, 275, H 195-303.
27. (b) Ramasamy, R. Aldose Reductase: A Novel Target for Cardioproective Effects. Curr. Drug Targets 2003, 4, 625-632.
28. (c) Kaneko, M.; Ramasamy, R. Aldose Reductase: A Key Player in Myocardial Ischemic Injury. Exer. Sci. Sport. Rev. 2004, 32, 19-23.
29. (d) Hwang, Y. C.; Kaneko, M.; Bakr, S.; Liao, H.; Lu, Y.; Lewis, E. R.; Yan, S.; Li, S.; Itakura, M.; Rui, L.; Skopicki, H.; Homma, S.; Schmidt, A. M.; Oates, P. J.; Szabolcs, M.; Ramasamy, R. Central Role for Aldose Reductase Pathway in Myocardial Ischemic Injury. FASEB J. 2004, 18, 1192-1199.
30. Ho, E. C. M.; Lam, K. S. L.; Chung, S. S. M.; Chung, S. K. Aldose Reductase Deficient Mice are Alleviated from the Depletion of GSH in the Peripheral Nerve and MNCV Deficit Associated with Diabetes. Diabetes 2001, 50 (Suppl. 2), A59.
31. (a) Demaine, A.; Cross, D.; Millward, A. Polymorphism of the Aldose Reductase Gene and Susceptibility to Retinopathy in Type I Daibetes Mellitus. Invest. Ophthalmol. Vis. Sci. 2000, 41, 4064-4068.
32. (b) Heesom, A. E.; Millward, A.; Demaine, A. G. Susceptibility to Diabetic Neuropathy in Patients with Insulin Dependent Diabetes Mellitus is Associated with a Polymorphism at the 5′ end of the Aldose Reductase Gene. J. Neurol. Neurosurg. Psychiatry 1998, 64, 213-216.
33. 1-tetrone (AS-3201) and Its Congeners. J. Med. Chem. 1998, 41, 4118-4129.
34. Bril, V.; Buchanan, R. A. Aldose Reductase Inhibition by AS-3201 in Sural Nerve from Patients with Diabetic Sensorimotor Polyneuropathy. Diabetes Care 2004, 27, 2369-2375.
35. (a) Malamas, M. S.; Hohman, T. C.; Millen, J.; Malamas, M. S.; Hohman, T. C.; Millen, J. Novel Spirosuccinimide Aldose Reductase Inhibitors Derived from Isoquinoline-1,3-diones: 2-[(4-Bromo-2-fluorophenyl) methyl]-6- fluorospiro[isoquinoline-4(11H),3′-pyrrolidine]-1,2′,3,5′(2H) -tetrone and Congeners. 1. J. Med. Chem. 1994, 37, 2043-2058.
36. (b) Hohman, T. C.; Bochenek, W. J.; Meng, X.; Neefe, L.; Beg, M.; Ari, D. T. Nerve Function and Biochemistry in Diabetic Patients Treated with ARI-509, a Novel Aldose Reductase Inhibitor. Diabetologia. 1997, 40, A552.
37. Johnson, B. F.; Nesto, R. W.; Pfeifer, R. W.; Slater, W. R.; Vinik, A. I.; Chyun, D. A.; Law, G.; Wackers, F. J.; Young, L. H. Cardiac Abnormalities in Diabetic Patients with Neuropathy: Effects of Aldose Reductase Inhibitor Administration. Diabetes Care 2004, 27, 448-454.
38. Mylari, B. L.; Armento, S. J.; Beebe, D. A.; Conn, E. L.; Coutcher, J. B.; Dina, M. S.; O'Gorman, M. T.; Linhares, M. C.; Martin, W. H.; Oates, P. J.; Tess, D. A.; Withbroe, G. J.; Zembrowski, W. J. A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofaran-2-sulfonyl) -2-H-pyridazin-3-one. J. Med. Chem. 2003, 46, 2283-2286.
39. Takabayashi, N. Synthesis of Pyridazine Derivatives. VI. Oxidation Products of Sulfur-containing Compounds of Pyridazine. J. Pharm. Soc. Jpn. 1956, 76, 1293-1296.
40. Turck, A.; Ple, N.; Pollet, P.; Queguiner, G. Metallation of tert-Butyl Sulfoxides, Sulfones and Sulfonamides of Pyridazine and Pyrazine. Metallation of Diazines. XX. J. Heterocycl. Chem. 1998, 35, 429-436.
41. Kukolja, S.; Crniæ, Z.; Kolbah, D. Nucleophilic Substitution, Demethylation and Methylation in Heterocyclic Series. Tetrahedron 1963, 19, 1153-1157.
42. Mylari, B. L.; Beyer, T. A.; Siegel, T. W. A Highly Specific Aldose Reductase Inhibitor: Ethyl 1-Benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and Its Congeners. J. Med. Chem. 1991, 34, 1011-1018.
43. (a) Subatomic and Atomic Crystallographic Studies of Aldose Reductase: Implications for Inhibitor Binding. Podjorny, A.; Cachau, R. E.; Schenider, T.; Van Zadt, M.; Joachiniak, A. Cell. Mol. Life Sci. 2004, 61, 769-773.
44. (b) Aldose Reductase Structures: Implications for Mechanism and Inhibition. El-Kabbani, O.; Ruiz, F.; Darmanian, C.; Chung, R. P. T. Cell. Mol. Life Sci. 2004, 61, 750-762.
45. Nitta, Y.; Yoneda, F.; Ohtaka, T.; Kato, T. Pyridazinone Derivatives. V. Synthesis of Derivatives of 6-Phenyl-3(2H)-Pyridazinone. Chem Pharm Bull (Tokyo) 1964, 12, 69-73.
46. Heinisch, G.; Langer, T. J. Pyridazines. LXVIII. Convenient Synthesis of Phenyl (6-Substituted 3-Pyridazinyl) Ketones via the Oxidative Decyanation Route. Heterocycl. Chem. 1993, 30, 1685-1690.
47. Stribling, D.; Mirrlees, D. J.; Harrison, H. E.; Earl, D. C. Properties of ICI 128, 436, a Novel Aldose Reductase Inhibitor, and Its Effects on Diabetic Complications in the Rat. Metabolism 1985, 34(4), 336-44.
48. (a) Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zembrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. Novel, Potent Aldose Reductase Inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2- benzothiazolyl]methyl]-1-phthalazineacetic Acid (zopolrestat) and Congeners. J. Med. Chem. 1991, 34, 108-122.
49. (b) Mylari, B. L.; Beyer, T. A.; Scott, P. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Zembrowski, W. J. Potent, Orally Active Aldose Reductase Inhibitors Related to Zopolrestat: Surrogates for Benzothiazole Side Chain. J. Med. Chem. 1992, 35, 457-465.
50. Wilson, D. K.; Tarle, I.; Petrash, J. M. Quiocho, F. A. Refined 1.8 A Structure of Human Aldose Reductase Complexed with the Potent Inhibitor Zopolrestat. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9847-9851.
51. Kato, K.; Nakayama, K.; Mizota, M.; Miwa, I.; Okuda, J. Properties of Novel Aldose Reductase Inhibitors, M16209 and M16287, in Comparison with Known Inhibitors. ONO-2235 and Sorbinil. Chem. Pharm. Bull. (Tokyo) 1991, 39, 540-545.
52. Robertson, M. J.; Barnes, J. C.; Drew, G. M.; Clark, K. L.; Marshall, F. H.; Michel, A.; Middlemiss, D.; Ross, B. C.; Scopes, D.; Dowle, M. D. Pharmacological Profile of GR117289 In Vitro: A Novel, Potent and Specific Non-peptide Angiotensin AT1 Receptor Antagonist. Br. J. Pharmacol. 1992, 107, 1173-1180.
53. Jones, J. F.; Mysinger, M.; Korzekwa, K. R. Computational Models for Cytochrome P450: A Predictive Electronic Model for Aromatic Oxidation and Hydrogen Atom Abstraction. Drug Metab. Dispos. 2002, 30, 7-12.
54. Lewis, D. F. V.; Sams, C.; Loizou, G. D. A Quantitative Structure-Activity Relationship Analysis on a Series of Alkyl Benzenes Metabolized by Cytochrome P450 2E1. J. Biochem. Mol. Toxicol. 2003, 17, 47-52.
55. Oates, P. J.; Beebe, D. A.; Coutcher, J. B.; Quian, Y.-Z.; Phillips, D.; Lowe, V.; Appelton, T.; Rauning, D.; O'Neill, S.; Mylari, B. L. Sorbitol Dehydrogenase Inhibition as Well as Aldose Reductase Inhibition Prevents Elevation of Urinary Albumin Excretion in Diabetic Rats. Diabetologia 2004, 47 (Suppl. 1), A398.
56. Bosron, W. F.; Prairie, R. L. Triphosphopyridine Nucleotide-linked Aldehyde Reductase. I. Purification and Properties of the Enzyme from Pig Kidney Cortex. J. Biol. Chem. 1972, 247, 4480-4485.
57. Vallee, B.; Hoch, F. Zinc: A Component of Yeast Alcohol Dehydrogenase, Proc. Natl. Acad. Sci. 1955, 41, 327.
58. Siegel, T. W.; Smith, S. R.; Ellery, C. A.; Williamson, J. R.; Oates, P. J. An Enzymatic Fluorimetric Assay for Fructose. Anal. Biochem. 2000, 280, 329-331.
59. Grubenmann, W.; Erlenmeyer, H. Ûber Bromierte Cumaron-derivate und ûber eine Neue Darstellung von Cumaronyl-3-essigsäure. Helv. Chim. Acta 1948, 31, 78.
60. Larock, R. C.; Stinn, D. E. Synthesis of Benzofurans Via Palladium-Promoted Cyclization of Ortho-Substituted Aryl Allyl Ethers. Tetrahedron Lett. 1988, 29, 4687-4690.
61. Barnse, R. A.; Gordon, L. Substituted Isobutyrophenones. J. Am. Chem. Soc. 1950, 72, 5308.
62. Chapman, N. B.; Clarke, K.; Iddon, B. Synthesis of Some 5-Substituted Benzo[6]thiophenes Related to Gramine. J. Chem. Soc. 1965, 774-777.